ES2201942B2 - Inhibidor de la captacion de monoamina. - Google Patents

Inhibidor de la captacion de monoamina.

Info

Publication number
ES2201942B2
ES2201942B2 ES200350052A ES200350052A ES2201942B2 ES 2201942 B2 ES2201942 B2 ES 2201942B2 ES 200350052 A ES200350052 A ES 200350052A ES 200350052 A ES200350052 A ES 200350052A ES 2201942 B2 ES2201942 B2 ES 2201942B2
Authority
ES
Spain
Prior art keywords
methyl
phenyl
oxy
aminopropane
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200350052A
Other languages
English (en)
Spanish (es)
Other versions
ES2201942A1 (es
Inventor
Edward Louis Mattiuz
John-Michael Sauer
William Joe Wheeler
David Taiwai Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23045157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2201942(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of ES2201942A1 publication Critical patent/ES2201942A1/es
Application granted granted Critical
Publication of ES2201942B2 publication Critical patent/ES2201942B2/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES200350052A 2001-03-06 2002-02-20 Inhibidor de la captacion de monoamina. Expired - Fee Related ES2201942B2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27373001P 2001-03-06 2001-03-06
US60/273730 2001-03-06
US600/273730 2001-03-06

Publications (2)

Publication Number Publication Date
ES2201942A1 ES2201942A1 (es) 2004-03-16
ES2201942B2 true ES2201942B2 (es) 2004-12-16

Family

ID=23045157

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200350052A Expired - Fee Related ES2201942B2 (es) 2001-03-06 2002-02-20 Inhibidor de la captacion de monoamina.
ES02713538T Expired - Lifetime ES2305221T3 (es) 2001-03-06 2002-02-20 Inhibidor de la captacion de monoamina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02713538T Expired - Lifetime ES2305221T3 (es) 2001-03-06 2002-02-20 Inhibidor de la captacion de monoamina.

Country Status (35)

Country Link
US (2) US20040082666A1 (enExample)
EP (1) EP1379492B1 (enExample)
JP (1) JP2004525912A (enExample)
KR (1) KR20030092012A (enExample)
CN (1) CN1229331C (enExample)
AP (1) AP2003002855A0 (enExample)
AT (2) ATE396170T1 (enExample)
AU (1) AU2002245385B2 (enExample)
BR (1) BR0207716A (enExample)
CA (1) CA2440161A1 (enExample)
CH (1) CH695982A5 (enExample)
CZ (1) CZ20032380A3 (enExample)
DE (1) DE60226715D1 (enExample)
DK (1) DK200301267A (enExample)
EA (1) EA005768B1 (enExample)
EC (1) ECSP034760A (enExample)
EE (1) EE200300419A (enExample)
ES (2) ES2201942B2 (enExample)
FI (1) FI20031191A7 (enExample)
GB (1) GB2389851B (enExample)
HR (1) HRP20030710A2 (enExample)
HU (1) HUP0303341A3 (enExample)
IL (1) IL157779A0 (enExample)
LT (1) LT5143B (enExample)
LU (1) LU91038B1 (enExample)
LV (1) LV13119B (enExample)
NO (1) NO20033921L (enExample)
NZ (1) NZ527431A (enExample)
OA (1) OA12494A (enExample)
PL (1) PL363840A1 (enExample)
SE (1) SE526598C2 (enExample)
SK (1) SK10632003A3 (enExample)
TR (1) TR200705146T1 (enExample)
WO (1) WO2002070457A1 (enExample)
ZA (1) ZA200306882B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1229331C (zh) * 2001-03-06 2005-11-30 伊莱利利公司 一元胺吸收的抑制剂
WO2005020976A2 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
WO2011027359A2 (en) * 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
DE102013022397A1 (de) 2013-12-19 2016-07-07 Metrax Gmbh Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage
GR1008819B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
CN107935848B (zh) * 2017-11-21 2020-12-22 中国农业科学院兰州畜牧与兽药研究所 一种六茜素衍生物及其制备方法和应用
JP2022506113A (ja) * 2018-10-31 2022-01-17 アプニメッド,インコーポレイテッド(デラウェア) 睡眠時無呼吸を治療するための方法及び組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
US5112619A (en) * 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
ZA921292B (en) * 1991-02-25 1993-08-23 Lilly Co Eli Treatment of lower urinary tract disorders.
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
WO2000058262A1 (en) 1999-03-29 2000-10-05 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
ATE309196T1 (de) 1999-04-09 2005-11-15 Lilly Co Eli Verfahren zur herstellung von 3-aryloxy-3- arylpropylamine und deren zwischenprodukte
EP1395253A2 (en) * 2000-11-15 2004-03-10 Eli Lilly And Company Treatment of anxiety disorders
CN1229331C (zh) * 2001-03-06 2005-11-30 伊莱利利公司 一元胺吸收的抑制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines

Also Published As

Publication number Publication date
KR20030092012A (ko) 2003-12-03
FI20031191L (fi) 2003-08-25
ATA90422002A (de) 2006-01-15
ATE396170T1 (de) 2008-06-15
US20040082666A1 (en) 2004-04-29
NO20033921D0 (no) 2003-09-04
IL157779A0 (en) 2004-03-28
SE526598C2 (sv) 2005-10-18
LV13119B (en) 2004-06-20
EE200300419A (et) 2004-02-16
HUP0303341A2 (hu) 2004-01-28
CZ20032380A3 (en) 2004-03-17
AP2003002855A0 (en) 2003-08-20
NO20033921L (no) 2003-11-05
ZA200306882B (en) 2004-12-03
DK200301267A (da) 2003-11-06
EA005768B1 (ru) 2005-06-30
AT414238B (de) 2006-10-15
GB0323169D0 (en) 2003-11-05
US20050209341A1 (en) 2005-09-22
EA200300978A1 (ru) 2004-02-26
HRP20030710A2 (en) 2004-08-31
HUP0303341A3 (en) 2007-03-28
GB2389851B (en) 2005-05-25
NZ527431A (en) 2005-05-27
DE60226715D1 (de) 2008-07-03
JP2004525912A (ja) 2004-08-26
EP1379492A1 (en) 2004-01-14
CA2440161A1 (en) 2002-09-12
WO2002070457A1 (en) 2002-09-12
PL363840A1 (pl) 2004-11-29
LT2003075A (en) 2004-03-25
LU91038B1 (fr) 2003-09-11
US7384983B2 (en) 2008-06-10
OA12494A (en) 2006-05-24
ECSP034760A (es) 2003-10-28
CH695982A5 (de) 2006-11-15
WO2002070457A8 (en) 2004-06-03
SE0302361D0 (sv) 2003-09-03
GB2389851A (en) 2003-12-24
SE0302361L (sv) 2003-09-03
TR200705146T1 (tr) 2008-02-21
FI20031191A7 (fi) 2003-08-25
ES2305221T3 (es) 2008-11-01
SK10632003A3 (sk) 2004-06-08
CN1229331C (zh) 2005-11-30
EP1379492B1 (en) 2008-05-21
AU2002245385B2 (en) 2007-01-18
LT5143B (lt) 2004-06-25
CN1494526A (zh) 2004-05-05
ES2201942A1 (es) 2004-03-16
BR0207716A (pt) 2004-03-23

Similar Documents

Publication Publication Date Title
ES2201942B2 (es) Inhibidor de la captacion de monoamina.
US11905276B2 (en) Bicyclic compound that acts as CRBN protein regulator
BRPI0818193B1 (pt) composto, composição farmacêutica, e, uso de um composto
PT87163B (pt) Processo para a preparacao de 1-fenil-3-naftaleniloxi-propanaminas
AU2002245385A1 (en) Inhibitor of monoamine uptake
JP5015919B2 (ja) 撮像用18f又は11c標識アルキルチオフェニルグアニジン
EP4299569B1 (en) Fused polycyclic substituted 5-carboxylic acid thienopyrimidine dione compound and use thereof
US20090069378A1 (en) Deuterium-enriched donepezil
US7183319B2 (en) Phenylethylamine derivatives and their use in the treatment of melanoma
US20090069431A1 (en) Deuterium-enriched milnacipran
ES2291135B1 (es) Procedimiento para la preparacion de tartrato de (r)-tolterodina.
AU2007201684A1 (en) Inhibitor of monoamine uptake
US20080312318A1 (en) Deuterium-enriched escitalopram
ES2266416T3 (es) Procedimiento para la preparacion de compuestos 2-(4-alquil-1-piperazinil)-benzaldehido y compuestos de -bencilidenilo por sustitucion nucleofila aromatica de 2-fluorobenzaldehido con 4-alquil-1-piperazina en agua como solvente.
ES2792875T3 (es) Procedimiento de síntesis de facetoperano
US7041851B2 (en) Fluorinated phenyl thiophenyl derivatives and their use for imaging serotonin transporters
AU2001275702B2 (en) Phenylethylamine derivatives and their use in the treatment of melanoma
US20110118358A1 (en) Deuterium-enriched salmeterol
AU2001275702A1 (en) Phenylethylamine derivatives and their use in the treatment of melanoma

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20040316

Kind code of ref document: A1

FD2A Announcement of lapse in spain

Effective date: 20101117